RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need.  RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.

©2015 RuiYi, All Rights Reserved.